The
masks are coated in zinc oxide nano-particles that destroy
bacteria, fungi and viruses, and the company says they can help
stop the spread of COVID-19.
"We believe we will complete the (IPO) process at the end of
this year," CTO Liat Goldhammer told Reuters. "We are targeting
a valuation of $50 million. We are doing the legal and
accounting process now."
A successful listing depends on many factors, including the
scale-up of production, the company said.
Goldhammer said Sonovia's masks are not certified for use by
medical professionals in operating and emergency rooms, which
use only disposable masks.
But tests of its fabric show effectiveness of nearly 99% against
viruses similar to COVID-19 and the fabric remains potent
through 100 washes at high temperatures, she said.
While COVID-19 is not available for testing of commercial
products, the material was tested at Austria's HygCen medical
lab this month using Vaccinia virus, which has similar
properties to the SARS-COVID family.
The tests showed "a good virucidal effect", according to the lab
report.
Some $18 million has been invested in the technology, which
began as research at Israel's Bar Ilan University. This includes
12 million euros ($13 million) in grants from the European
Union.
Goldhammer said that as companies bring people back to work
after the coronavirus crisis and need masks, many are concerned
about the environment and are seeking alternatives to single-use
N95 masks.
Sonovia's clients include German manufacturers Bruckner and
Weber Ultrasonics, and hospitals in Germany and the United
States. The company did not provide figures for sales of the
masks, which are also sold online to consumers.
($1 = 0.9138 euros)
(Editing by Timothy Heritage)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|